Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GEN1079 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| GEN1079 | DRUG | Concentrate for solution. |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
GEN1079 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities. The drug is being studied to evaluate its safety and preliminary efficacy in patients with advanced solid tumors.
GEN1079 is being developed by Genmab A/S, a biotechnology company listed on the Nasdaq under the ticker symbol GMAB. Genmab is responsible for the clinical development of this investigational small molecule therapy for advanced solid tumors.
GEN1079 is currently in Phase 1 clinical development. The drug is being evaluated in an early-stage clinical trial to assess its safety and preliminary efficacy in patients with advanced solid tumors. It is an investigational agent and has not yet received regulatory approval.
GEN1079 is being studied in a Phase 1 clinical trial registered as NCT07387068. This trial is currently recruiting participants and aims to evaluate the safety and preliminary efficacy of GEN1079 in patients with advanced solid tumors. The study is designed to enroll approximately 121 participants.
Yes, GEN1079 is a small molecule therapeutic agent. It is being developed as an oral or injectable medication for the treatment of advanced solid tumors. As a small molecule, it is designed to interact with specific cellular targets to exert its anti-cancer effects.